It remains to be elucidated, however, whether metformin's ability to strongly activate the ATM/Chk2-regulated DDR checkpoint [62] is a critical event that prevents neoplastic epithelium to progress unimpeded into invasive cancer in individuals without type 2 diabetes. Here, CHEK2 is linked to cancer.